oric-944
oric-944: sourced relationships with 1 company · 1 clinical trial tracked.
oric-944 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect oric-944 to ORIC; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could oric-944 → ORIC affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Oric Pharmaceuticals, Inc. (ORIC) | Phase 1 |
Clinical Trial Registry Records (1)
An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer
Primary endpoint: Recommended Phase 2 Dose (RP2D)
Interventionalopen275 targetStarted 2022-06Completion 2028-0427 sites · Australia, Spain, United Kingdom, United StatesORIC Pharmaceuticals
Frequently asked questions
Which companies have sourced relationships with oric-944?
oric-944 has dated SEC/FDA relationship records for Oric Pharmaceuticals, Inc..
How many clinical trials involve oric-944?
BioSniper tracks 1 clinical trial involving oric-944.